Summary
Pfizer Inc. (PFE) filed a Current Report on Form 8-K on November 15, 2007, to furnish documents formatted in XBRL (eXtensible Business Reporting Language). This filing is part of the SEC's voluntary XBRL pilot program and is intended to test the XBRL format and technology. It includes condensed consolidated financial statements (Income, Balance Sheets, and Cash Flows) for periods ending September 30, 2007, and comparable prior periods, as originally filed in Pfizer's Form 10-Q on November 5, 2007. It is critical for investors to understand that this 8-K filing and its accompanying XBRL data are not the official financial statements and should not be relied upon for investment decisions. The company explicitly advises users that the XBRL information is unaudited and not subject to the same liabilities as officially filed SEC documents. Investors should continue to refer to the official filings for accurate financial reporting and decision-making.
Key Highlights
- 1Pfizer is participating in the SEC's voluntary XBRL pilot program to test the XBRL reporting format and technology.
- 2The 8-K filing furnishes XBRL-formatted financial data, including Condensed Consolidated Statements of Income, Balance Sheets, and Cash Flows.
- 3The XBRL data pertains to Pfizer's financial performance for periods ending September 30, 2007, and comparative prior periods.
- 4This XBRL data is derived from Pfizer's Form 10-Q filing dated November 5, 2007.
- 5Crucially, the XBRL information presented in this 8-K is unaudited and not considered official financial statements.
- 6Investors are strongly advised by Pfizer and SEC rules not to rely on this XBRL data for investment decisions.
- 7This filing is for informational purposes related to XBRL technology testing, not for substantive financial disclosure updates.